Ambrx Biopharma, Inc. is a clinical-stage biologics company, which engages in discovering and developing a novel class of engineered precision biologics (EPBs). Using its proprietary expanded genetic code technology platform, it allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, and ARX305. The company was founded on August 11, 2023 and is headquartered in La Jolla, CA.